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EFFECT O F HOLOTHURIN ON SARCOMA 180 AND B-16
MELANOMA TUMORS I N MICE'

bY
S. D. CAIRNS2 and C. A. OLMSTED
Department of Biological Sciences, Louisiana State
University in New Orleans, Louisiana 70122
ABSTRACT
Holothurin, a biotoxic principle from the Cuvierian glands of the
Bahamian sea-cucumber, Actinopyga agassixi, was studied as a n antitumor agent capable of retarding tumor growth and prolonging the
life of tumor-bearing mice. White Swiss mice injected with Sarcoma
180 had a mean survival time of 18.1 days with a n average weight
gain representing tumor and ascites fluid accumulation amounting t o
25.1 grams in 15 days. Of five white Swiss mice with Sarcoma 180 receiving 0.15 mg Holothurin every other day, one was alive a t 57 days
and the average weight gain of the group was 10.4 grams in 15 days.
White Swiss mice with Sarcoma 180 which survived the lethal effects
of slightly higher doses of Holothurin also had prolonged survival
times and negligible tumor growth. C57-Bl-6J mice with B-16 melanoma tumors did not show increased survival time using the same
doses of Holothurin that were effective in white Swiss mice. Toxicity
tests indicated that the safe upper limit for intraperitoneal Holothurin
injection in white Swiss mice was 0.10 mg/day, 0.15 mg given every
other day, and up to 0.30 mg given in a single injection. Similar tests
with C57 black mice showed survival with as much as 0.60 mg Holothurin in a single subcutaneous injection. Holothurin was found to be
250 to 500 times more effective in causing red blood cell hemolysis
than saponin and thus appears to have some action on living cells in
addition t o its surfactant action.
INTRODUCTION
Cancer chemotherapy began in 1946 when nitrogen mustard was
used in treating leukemia patients. During the next 15 years only some
thirty drugs were used in cancer chemotherapy but screening of many
thousands of compounds was carried out each year (Clark 1961). Although marine invertebrates provide a particularly rich source of
compounds with biological activity in mammalian species, less than
1 This work was supported in p a r t by the Cancer Association of Greater New
Orleans, Inc.
2 Present address : Department of Biological Oceanography, the Rosenstiel
School of Marine and Atmospheric Sciences, University of Miami, Miami, Florida

33129.
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17. of all marine invertebrates thought to possess biotoxic substances
have been investigated and of those, only a dozen have been thoroughly investigated pharmacologically (Halstead 1965) .
Small concentrations of a crude water extract made from the
whole body of the Bahamian sea-cucumber, Actinopyga agassixi, was
found t o be lethal t o mice and fish and t o have some tumor cell inhibitory action in vitro (Nigrelli and Zahl 1952). The active principle of
this crude extract was found to be concentrated in the Cuvierian tubules located in the sea-cucumber respiratory tree and was named Holothurin (Chanley et al. 1955). Holothurin was the first known steroid
saponin of animal origin (Nigrelli et al. 1959). Chemical analysis of
Holothurin indicates that it is highly soluble in water, non-volatile,
heat stable, and exhibits surface-active properties (Nigrelli and Jakowska 1960). Holothurin appears to consist of a few steroid aglycones that are bound individually to four monosaccharide molecules.
A provisional formula has been proposed (Alender and Russell 1966).
See Fig. 1.
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Figure 1. Holothurin formula. Proposed structure for Holothurin molecule, a steroid saponin of animal origin; the monosaccharide groups represented by SI-S4are, respectively, D-glucose, D-xylose, D-quinovose, and
3-o-methyl glucose.
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Holothurin is highly toxic to many types of organisms in very
small concentrations. I t retards onion root tip development (Nigrelli
and Jakowska 1960) and fruit fly pupation (Goldsmith, Osburg and
Nigrelli 1958) a t 1000 ppm, alters regeneration of planarians a t 100
ppm (Quaglio et al. 1957), is lethal to the “pearl” fish Caiapiis a t
1 ppm and affects sea urchin development at 0.01 ppm (Ruggieri and
Nigrelli 1960). Holothurin exhibits a hemolytic effect on red blood
cells and reduces the size of a subcutaneously injected Sarcoma 180
tumor in white Swiss mice (Nigrelli 1952). Krebs-2 ascites tumors in
white Swiss mice are also inhibited by Holothurin (Sullivan, Ladue
and Nigrelli 1955).
The present study demonstrates inhibition of Sarcoma 180 tumors in white Swiss mice but not of B-16 melanoma tumors in C57
Black 6 J mice. Toxicity of Holothurin was estimated by measuring its
effects on red blood cell hemolysis and by lethal-dose measurements in
mice. It appears that the anti-tumor activity of Holothurin is not only
dose-dependent but that the effective dose is determined by the sensitivity of the species to the lethal effects of Holothurin.
MATERIALS AND METHODS

Holothurin: The Holothurin referred to in this paper was a
“crude extract’’ obtained from Dr. Ross Nigrelli and was made from
the sun-dried, powdered Cuvierian glands of Bahamian sea-cucumbers, Actinopvga ayassixi.
Red Blood Cell Hemolysis Tests U s i n g Holothtwi?t arid Sapo?iin :
Fresh red blood cells were obtained from white Swiss mice just prior
to testing the hemolytic effects of Holothurin and saponin of plant
origin. The blood was obtained by cardiac puncture while the mice
were under light ether anesthesia. Approximately 5 ml of blood was
diluted in 100 ml of balanced-saline solution buffered at pH 7.4 (Olmsted 1967) containing calcium oxalate (0.1 ) to prevent coagulation.
A serial dilution of Holothurin was prepared ranging from 2 mg/ml
to 0.001 mg/ml and a similar series of dilutions of saponin was made
for comparison.
One ml of diluted blood was added to 5 ml of each of several concentrations of both Holothurin and saponin. The test tube was centrifuged 1 minute after mixing the contents and the optical density of
the supernatant was measured using a spectrophotometer set at 540
mu. The degree of hemolysis was estimated by the concentration of
hemoglobin in the supernatant. These values were compared to 100%
hemolysis values obtained either by using water only as the diluent or
by using a high concentration of Holothurin or saponin.

Holothzwin Toxicity i)z Mice : All Holothurin injections were
given at dosages determined by previous tests done in this laboratory
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on normal, non-tumor-bearing mice. Tests to determine the lethal and
sub-lethal intraperitoneal doses of Holothurin in white Swiss mice
were carried out using several concentrations given daily, given on
alternate days, and for several concentrations given in a single injection. The dosages of Holothurin given to the white Swiss mice bearing
Sarcoma 180 tumors were based on these data. The dosages of Holothurin given to the C57 black mice bearing B-16 melanoma tumors
was based on the effective doses of Holothurin given to tumor-bearing
white Swiss mice. In addition, a test of toxicity of a single subcutaneous injection of Holothurin was carried out using several concentrations of Holothurin given to normal, non-tumor-bearing C57-Bl-6J
mice.

Holothurin Administration t o Mice Bearing Sarcoma 180: Sarcoma 180 cells and the white Swiss mice were obtained from the Gulf
South Research Institute in New Orleans. The mice were inoculated
intraperitoneally with 0.5 ml of Sarcoma 180 ascites fluid containing
11.6 X lo6 cells/ml. Groups of five mice received daily injections of
Holothurin a t 0.01, 0.05, 0.10, and 0.15 mg each, and three groups received injections of Holothurin every other day in the amounts of
0.10, 0.15 and 0.20 mg each. Twelve mice received Sarcoma 180 inoculations, but no Holothurin. The survival time was recorded for each
mouse and the mice were weighed individually before inoculation with
tumor cells and a t &day intervals during the course of the experiments.
Holothurin Administration t o Mice Bearing €3-16 Melanoma : A
single C57-Bl-6J mouse with a B-16 melanoma tumor was used as the
source for all of the B-16 melanoma used in this study. The tumorbearing donor mouse was obtained from the Department of Surgery
at Tulane Medical School. The C57-Bl-6J mice used in the experiments here were obtained from the Roscoe B. Jackson Memorial Laboratory in Bar Harbor, Maine. The solid tumor was taken from the
donor mouse under light ether anesthesia and was minced with scissors in a tissue culture nutrient medium containing serum (Olmsted
1967). Several small pieces of the minced tumor were trochared subcutaneously into the left side of thirty-five recipient male mice. Thirty
of these mice were used for the experiments reported here. Daily injections of 0.05, 0.10, and 0.15 mg Holothurin were given to each of
the five tumor-bearing mice in three groups and five tumor-bearing
mice in another group were each given 0.20 mg Holothurin every
other day. Five mice without melanoma, and ten mice with melanoma
tumors, were also maintained but not given Holothurin. All Holothurin injections were given subcutaneously near the region of tumor
implantation in 0.10 ml volumes, and were given over a 13-day period.
The survival time was recorded for each mouse, and the mice were
weighed in groups of five before tumor implantation and at &day intervals during the course of the experiments.
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Hemolysis Tests : Minimum concentrations of Holothurin and
saponin that produced complete hemolysis were found to be 0.001
mg/ml of Holothurin and 0.25-0.50 mg/ml of saponin indicating that
Holothurin was 250 to 500 times more active as a hemolytic agent
than saponin.
Holothurin Toxicity in Mice : Holothurin treatment of tumorbearing white Swiss mice a t the level of 0.15 mg/day was lethal at 3
t o 8 days with a mean of 4.2 days. See Table 1. Toxicity tests on other
Table 1.
Effects of Holothurin on White Swiss Mice with Sarcoma 180
Bod7 Weight

No.
of
Mice

-

Sex

:hange

(ma)

Frequency
of
i n j ect i o n

Survival
Time
(days)

5th
day
(g>

& .(g>

0

18.1
(15-21)
19.2
(15-22)
17.8
(16-23)
16.3
(14-19)
16.8
(15-20)
26.4
(16-58)

+2.3

+13.0

-25.1

+2.0

+12.7

127.6

+13.8

k33.0

-1.4

+

8.2

k30.7

-1.1

+lo. 1

t29.4

-1.0

+

i-10.4

4.2
(3-8)
22.2
(10-47)

died

--

--

-1.8

0

0

Dose

12

F

0

5

F

0.01

daily

5

F

0.05

daily

5

F

0.10

daily

5

F

0.10

5

F

0.15

5

F

0.15

alternate
days
alternate
days
daily

5

M

0.20

alternate
days

0

10th
day

2.9

15th
day

groups of normal, non-tumor-bearing white Swiss mice indicated that
either 0.10 mg/day or 0.15 mg given on alternate days was a safe
upper limit for intraperitoneal Holothurin administration. Additionally, 0.30 mg Holothurin in a single injection could be tolerated, but
more than this amount in a single injection was lethal. Toxicity tests
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on C57-Bl-6J mice without B-16 melanoma tumors indicated that
these mice could survive single subcutaneous injections of Holothurin
as high as 0.60 mg.

EfSect o f Holothurin on White Swiss Mice with Sarcoma 1 8 0 :
Twelve tumor-bearing mice that were not treated with Holothurin
lived for a n average of 18.1 days after tumor cell inoculation. These
mice gained a n average of 25.1 g by the fifteenth day after tumor cell
inoculation. This increase in body weight represents the extent of increase in tumor size and ascites fluid accumulation since body weight
increase due to growth of the animal during this time would have
been negligible. The tumor-bearing animals receiving 0.15 mg Holothurin on alternate days had a mean survival time of 26.4 days representing a n increase in survival time of 46%, and a mean weight gain
a t 15 days of 10.4 g representing a 60 to 70% decrease in tumor
growth and ascites fluid accumulation. One of the mice in this high
Holothurin dose group had a weight gain of only 5.1 g and was still
alive after 58 days. Three of the mice receiving 0.20 mg Holothurin
every other day died in less than 12 days probably as a result of Holothurin overdose. Of the other two mice in the 0.20 mg group, one
lived for 30 days and the other for more than 47 days and both had
negligible weight gain during this period of time indicating complete
tumor suppression. The four groups of tumor-bearing mice receiving
less than 0.15 mg of Holothurin per injection did not show any significant increase in survival time or decrease in weight gain. See
Table 1.

EfSects of Holothurin on C57-Bl-6J Mice with B-16 Melanoma:
Ten C57-Bl-6J mice not injected with Holothurin lived for an average
time of 29.4 days after B-16 melanoma inoculation with a range of
18 to 43 days. The animals with malignant melanoma tumors decreased in total body weight. Normal, non-tumor-bearing C57-Bl-6J
mice of comparable age to the tumor-bearing mice all gained weight
on the diet and the conditions'of this experiment. Measurement of
body weight was not a valid indicator of tumor growth or of Holothurin effectiveness, as in the case of mice with Sarcoma 180, because
the melanoma tumor grows in a small solid mass and does not induce
ascites fluid accumulation. As the Holothurin dosages used here were
comparable to the effective doses for white Swiss mice bearing Sarcoma 180 tumors, and were well below the toxic levels of Holothurin
for C57-Bl-6J mice, none of the animals in this experiment showed
any increase in the survival time. See Table 2.
DISCUSSION

The crude extract of Holothurin used here was probably more
potent than purified preparations would be. Upon purification, the
anti-tumor principle is apparently lost or considerably reduced in con-
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Table 2.
Effects of Holothurin on C57-Bl-6J Mice with Melanoma

-No.
of

Mi CE
-

-1
Body Weigh
Frequency
of
i nj ect i o n

Sei Dose
(ma)
I

10

M

0

5

M

0.05

daily

5

M

0.10

daily

5

M 0.15

daily

5

M

-

0.20

0

,
~

I

I

LI

alternate
days
I

e
-

Survival
Time
(days)

10th
20th
day
day
day
0(g> (g> (g>

29.4
(18-43)
25.6
(20-42)
22.7
(19-26)
24.4
(20-35)
29.6
(25-33)

to.4

-0.7

-0.8

-0.3

-1.1

-3.4

-3.5

-2.5

-4.1

-4.8

-5.4

-4.4

-3.1

-3.5

-4.3

-4.5

-2.6

-3.5

-3.6

-3.3

5th
day

-

centration (Chanley et al. 1960). One sample of purified Holothurin
showed a tenfold-loss in hemolytic activity, and no anti-tumor activity (Nigrelli and Jakowska 1960).
Although the crude extract of Holothurin is effective against various tumors (Nigrelli 1952, and Sullivan, Ladue and Nigrelli 19551,
the present study demonstrates that Holothurin is apparently not effective at the same dose levels in differing species of mice. Larionov
(1967) suggests that a natural biological product should be more promising as a chemotherapeutic agent than a synthetic compound. The
same author has stated that the maximum effective acceptable dosage
of a n anti-tumor compound is close to the dosage which kills the
animal, whereas a decrease in dosage, even slight, leads to a sharp
drop in effectiveness. The narrow threshold is seen here in regard t o
the ineffectiveness of the lower concentrations of Holothurin on the
Sarcoma 180 tumors, and the lethal effect of 0.20 mg given over a
period of several alternate days to the tumor-bearing mice. Due to the
narrow range of effective concentrations of Holothurin in relation to,
its lethal dose, i t is likely that the ineffectiveness of Holothurin in the
C57-Bl-6J mice bearing B-16 melanomas was a reflection of the tolerance to higher doses of Holothurin in these animals. There is no indication that Holothurin, or any other chemotherapeutic agent, would
have differing effects in male and female tumor-bearing mice although
profound metabolic differences between male and female rats and
mice are well-known (Olmsted 1969). However, the differences seen
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in this study could also be due to differences in the injection site or in
the types of tumor. While this consideration presents many variables,
the Sarcoma 180 tumor grows best in white Swiss mice and the B-16
melanoma grows best in C57-Bl-6J mice. Further, it should be noted
that the mean survival time of the untreated mice with the two different types of tumor was about the same, i.e., about 3 to 4 weeks
after tumor inoculation. The hypothesis is further supported by the
finding that Holothurin is many times more effective in causing hemolysis than saponin when living red blood cells are used in the test
system.
Other hemolysis experiments similar to those described here have
shown that between 0.04 and 0.10 mg of the crude extract of Holothurin would cause complete hemolysis, while 0.08 to 0.10 mg of saponin was required for the same effect (Nigrelli and Jakowska 1960).
The apparent 40 to 100-fold discrepancy between the findings of Nigrelli and Jakowska and the findings of the present study could be accounted for by the use of different dilutions of red blood cells, or by
differences in the age of red blood cells used, or by species effects.
Nigrelli and Jakowska's data suggest that Holothurin is only slightly
more effective in causing hemolysis than saponin, while in the present
study using red blood cells that were freshly obtained from mice just
prior to testing it would appear that Holothurin is some 250 to 500
times more effective than saponin in causing hemolysis. Since a number of studies have shown Holothurin to have profound biological effects in concentrations as low as 0.01 ppm it is not surprising that
this biotoxic principle is much more effective than saponin on fresh
red blood cells. It would therefore appear that the action of Holothurin involves more than a surface tension lowering effect on living
cells.
Because Holothurin is an effective anti-tumor agent at concentrations only slightly lower than the lethal dose, it might be tentatively hypothesized t h a t Holothurin is acting on some process common
to all cells, not just tumor cells. However, no studies have been done
on the metabolic effects of Holothurin. The studies reported here indicate that the mode of action of Holothurin in retarding tumor growth
and prolonging life of tumor-bearing mice is probably different from
the action of a surfactant such as saponin. It is likely that the energy
requirements of the white Swiss mice with Sarcoma 180 differed from
those of the C57-Bl-6J mice bearing B-16 melanoma tumors. Other
studies from this laboratory on the C57-Bl-6J mice with B-16 melanoma tumors have shown that the growth of melanoma tumor occurs
at the expense of the anabolic processes of the host mouse. Structural
phospholipids synthesized by the tumor were shown to be derived
from synthesis in the liver (Terranova, Hardy and Olmsted 1970).
Although several experiments have been reported in the literature
regarding saponin, none have shown saponin to have any anti-tumor
activity in vivo. It is likly that saponin destroys cells simply by its
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action to lower surface tension starting with the plasma membrane
and continuing its action on membranes of other cellular constituents
in proportion to the concentration of saponin used. While the action
of Holothurin has some yet unknown effect other than, or in addition
to, its surfactant effect, it is likely that i t causes a n inhibition of an
active, or energy-dependent, physiological process.
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